TAMs expressing TREM2 are a potential therapeutic target (from Fig. 2F of Cao et al., Cancer Immunol Res 2019)

Understanding the mechanisms underlying resistance to anti–PD-1 therapy is key to developing new therapeutics. Binnewies et al. find that human and mouse immunosuppressive tumor-associated macrophages (TAM) express triggering receptor expressed on myeloid cells 2 (TREM2) and that the presence of these cells in the tumor microenvironment correlates with an exhausted T-cell state in human tumors and anti–PD-1 resistance in mouse models of cancer. A TREM2-specific antibody promotes antitumor immunity in mice by depleting TAMs, leading to enhanced CD8+ T-cell function. It also reverses anti–PD-1 resistance, highlighting the potential of targeting TREM2 to treat patients with anti–PD-1–resistant tumors.

Binnewies M, …, Sriram V. Cell Rep 2021 Oct 19;37:109844.

Loss of antigen can have an impact on therapy efficacy (by Silverisdead via Flickr)

Tumor loss of target antigen(s) can lead to resistance...

You do not currently have access to this content.